170 related articles for article (PubMed ID: 35842124)
1. Impact of Rituximab and Corticosteroids on Late Cytopenias Post-Chimeric Antigen Receptor T Cell Therapy.
Iqbal M; Bansal R; Yassine F; Gandhi S; Rosenthal A; Moustafa MA; Li Z; Craver EC; Mohty R; Murthy H; Ayala E; Tun H; Munoz J; Castro J; Lin Y; Kharfan-Dabaja MA
Transplant Cell Ther; 2022 Oct; 28(10):668.e1-668.e6. PubMed ID: 35842124
[TBL] [Abstract][Full Text] [Related]
2. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
3. Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma.
Zhou J; Zhang Y; Shan M; Zong X; Geng H; Li J; Chen G; Yu L; Xu Y; Li C; Wu D
Front Immunol; 2022; 13():997589. PubMed ID: 36131934
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of eltrombopag in patients with post-CAR T cytopenias.
Wesson W; Ahmed N; Rashid A; Tabak C; Logan E; Marchena-Burgos J; Nelson M; Davis JA; McGann M; Shune L; Hoffmann M; Abdallah AO; Hashmi H
Eur J Haematol; 2024 Apr; 112(4):538-546. PubMed ID: 38044594
[TBL] [Abstract][Full Text] [Related]
5. Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors.
Xia Y; Zhang J; Li J; Zhang L; Li J; Fan L; Chen L
Ann Med; 2022 Dec; 54(1):2951-2965. PubMed ID: 36382675
[TBL] [Abstract][Full Text] [Related]
6. Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma.
Wu J; Cao Y; Zhang Q; Liu W; Zhou X; Ming X; Meng F; Zhang Y; Li C; Huang L; Wei J; Zheng M; Zhang S; Zhang T; Zhu X; Wang N; Wang J; Wang G; Zhou J; Liu B; Xiao Y
Front Immunol; 2022; 13():879983. PubMed ID: 35669773
[TBL] [Abstract][Full Text] [Related]
7. [The characteristics and impact on prognosis of cytopenia after anti-BCMA-CAR-T therapy in patients with relapsed and refractory multiple myeloma].
Shen XX; Yao Y; Xia Y; Jin YY; Zhang R; Li JY; Chen LJ
Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(7):507-513. PubMed ID: 38317362
[No Abstract] [Full Text] [Related]
8. Recapitulated Late-Onset Inflammatory Toxicities and Progressive Dysautonomia with Persistence of Central Memory CD4+ Chimeric Antigen Receptor T Cells in a Case of Transformed Follicular Lymphoma: Case Report.
Nishimoto M; Takakuwa T; Kuno M; Makuuchi Y; Okamura H; Nakashima Y; Koh H; Namba H; Itoh Y; Hino M; Nakamae H
Acta Haematol; 2023; 146(4):338-342. PubMed ID: 37088083
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy.
Davis JA; Sborov DW; Wesson W; Julian K; Abdallah AO; McGuirk JP; Ahmed N; Hashmi H
Transplant Cell Ther; 2023 Sep; 29(9):567-571. PubMed ID: 37225044
[TBL] [Abstract][Full Text] [Related]
10. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
11. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
12. Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party.
Penack O; Peczynski C; Koenecke C; Polge E; Kuhnl A; Fegueux N; Daskalakis M; Kröger N; Dreger P; Besley C; Schanz U; Bloor A; Ganser A; Forcade E; Corral LL; Passweg JR; Novak U; Moiseev I; Schoemans H; Basak GW; Chabannon C; Sureda A; Averbuch D; Glass B; de la Camara R; Peric Z
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072350
[TBL] [Abstract][Full Text] [Related]
13. Hematologic cytopenia post CAR T cell therapy: Etiology, potential mechanisms and perspective.
Si X; Gu T; Liu L; Huang Y; Han Y; Qian P; Huang H
Cancer Lett; 2022 Dec; 550():215920. PubMed ID: 36122628
[TBL] [Abstract][Full Text] [Related]
14. Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience.
Schaefer A; Huang Y; Kittai A; Maakaron JE; Saygin C; Brammer J; Penza S; Saad A; Jaglowski SM; William BM
Cancer Manag Res; 2021; 13():8901-8906. PubMed ID: 34876852
[TBL] [Abstract][Full Text] [Related]
15. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.
Rejeski K; Perez A; Sesques P; Hoster E; Berger C; Jentzsch L; Mougiakakos D; Frölich L; Ackermann J; Bücklein V; Blumenberg V; Schmidt C; Jallades L; Fehse B; Faul C; Karschnia P; Weigert O; Dreyling M; Locke FL; von Bergwelt-Baildon M; Mackensen A; Bethge W; Ayuk F; Bachy E; Salles G; Jain MD; Subklewe M
Blood; 2021 Dec; 138(24):2499-2513. PubMed ID: 34166502
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
[TBL] [Abstract][Full Text] [Related]
17. Apoptosis of Hematopoietic Stem Cells Contributes to Bone Marrow Suppression Following Chimeric Antigen Receptor T Cell Therapy.
Read JA; Rouce RH; Mo F; Mamonkin M; King KY
Transplant Cell Ther; 2023 Mar; 29(3):165.e1-165.e7. PubMed ID: 36592718
[TBL] [Abstract][Full Text] [Related]
18. The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma.
Lutfi F; Holtzman NG; Kansagra AJ; Mustafa Ali M; Bukhari A; Yan J; Samanta S; Gottlieb D; Kim DW; Matsumoto LR; Gahres N; Ruehle K; Lee ST; Law JY; Kocoglu MH; Atanackovic D; Yared JA; Hardy NM; Molitoris J; Mohindra P; Rapoport AP; Dahiya S
Br J Haematol; 2021 Nov; 195(3):405-412. PubMed ID: 34500492
[TBL] [Abstract][Full Text] [Related]
19. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
Front Immunol; 2021; 12():755549. PubMed ID: 34777367
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]